Strides Pharma Releases FY26 Business Responsibility & Sustainability Report
Strides Pharma Science Ltd has submitted its Business Responsibility and Sustainability Report (BRSR) for the financial year ended March 31, 2026. The report, filed as per SEBI regulations, details the company's corporate identity, operational structure, and market presence. It covers standalone financial disclosures and consolidated other disclosures for Strides and its wholly-owned Indian subsidiary, Arcolab. The company operates in the manufacturing of pharmaceuticals, with 100% turnover from this segment. Strides serves a global market, with exports contributing 90.66% to its standalone turnover. The report also outlines employee and worker statistics as of FY26, with a total of 2,810 employees and 2,584 workers.
Key Highlights
- Strides Pharma filed its FY26 BRSR report as per SEBI regulations.
- Company's core business is pharmaceutical manufacturing, contributing 100% to turnover.
- Exports constitute 90.66% of standalone turnover.
- The report covers standalone financial and consolidated operational data.
- Detailed employee and worker statistics for FY26 are included.
Price Impact
More from STAR